uniQure reports 2024 EPS ($4.92), consensus ($3.73)

Reports 2024 revenue $27.1M vs. $15.8M last year. The company expects cash, cash equivalents and investment securities will be sufficient to fund operations through the second half of 2027. “This past year was transformative for uniQure (QURE), marked by significant clinical and operational progress,” stated Matt Kapusta, CEO. “On the clinical front, we made great strides advancing AMT-130 for Huntington’s disease, including securing alignment with the FDA on key elements of the Accelerated Approval pathway, a major milestone that brings us closer to delivering the first potentially disease-modifying treatment for this devastating condition. With this regulatory clarity, we have initiated BLA-readiness activities and look forward to further engagement with the FDA throughout the first half of 2025. Our RMAT designation has enabled a productive and expedited dialogue with the FDA, which we will continue leveraging to advance AMT-130 through the regulatory process as rapidly as possible. This is welcome news for patients awaiting further development of our groundbreaking therapies.”